Cargando…

Model-Based Meta-Analysis of Relapsing Mouse Model Studies from the Critical Path to Tuberculosis Drug Regimens Initiative Database

Tuberculosis (TB), the disease caused by Mycobacterium tuberculosis (Mtb), remains a leading infectious disease-related cause of death worldwide, necessitating the development of new and improved treatment regimens. Nonclinical evaluation of candidate drug combinations via the relapsing mouse model...

Descripción completa

Detalles Bibliográficos
Autores principales:	Berg, Alexander, Clary, James, Hanna, Debra, Nuermberger, Eric, Lenaerts, Anne, Ammerman, Nicole, Ramey, Michelle, Hartley, Dan, Hermann, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2022
Materias:	Clinical Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8923195/ https://www.ncbi.nlm.nih.gov/pubmed/35099274 http://dx.doi.org/10.1128/aac.01793-21

Ejemplares similares

Activity of a Long-Acting Injectable Bedaquiline Formulation in a Paucibacillary Mouse Model of Latent Tuberculosis Infection
por: Kaushik, Amit, et al.
Publicado: (2019)

Bactericidal and Sterilizing Activity of a Novel Regimen with Bedaquiline, Pretomanid, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis
por: Li, Si-Yang, et al.
Publicado: (2017)

Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis
por: Xu, Jian, et al.
Publicado: (2019)

Next-Generation Diarylquinolines Improve Sterilizing Activity of Regimens with Pretomanid and the Novel Oxazolidinone TBI-223 in a Mouse Tuberculosis Model
por: Li, Si-Yang, et al.
Publicado: (2023)

Using Dynamic Oral Dosing of Rifapentine and Rifabutin to Simulate Exposure Profiles of Long-Acting Formulations in a Mouse Model of Tuberculosis Preventive Therapy
por: Chang, Yong S., et al.
Publicado: (2023)

Mechanistic Modeling of Mycobacterium tuberculosis Infection in Murine Models for Drug and Vaccine Efficacy Studies
por: Zhang, Nan, et al.
Publicado: (2020)

Comparative Efficacy of the Novel Diarylquinoline TBAJ-587 and Bedaquiline against a Resistant Rv0678 Mutant in a Mouse Model of Tuberculosis
por: Xu, Jian, et al.
Publicado: (2021)

Comparative Efficacy of the Novel Diarylquinoline TBAJ-876 and Bedaquiline against a Resistant Rv0678 Mutant in a Mouse Model of Tuberculosis
por: Almeida, Deepak, et al.
Publicado: (2021)

Drug distribution and efficacy of the DprE1 inhibitor BTZ-043 in the C3HeB/FeJ mouse tuberculosis model
por: Ramey, Michelle E., et al.
Publicado: (2023)

Dual mTORC1/mTORC2 Inhibition as a Host-Directed Therapeutic Target in Pathologically Distinct Mouse Models of Tuberculosis
por: Tasneen, Rokeya, et al.
Publicado: (2021)

Comparative Analysis of Pharmacodynamics in the C3HeB/FeJ Mouse Tuberculosis Model for DprE1 Inhibitors TBA-7371, PBTZ169, and OPC-167832
por: Robertson, Gregory T., et al.
Publicado: (2021)

Advancing the Therapeutic Potential of Indoleamides for Tuberculosis
por: Lun, Shichun, et al.
Publicado: (2019)

Investigation of Elimination Rate, Persistent Subpopulation Removal, and Relapse Rates of Mycobacterium tuberculosis by Using Combinations of First-Line Drugs in a Modified Cornell Mouse Model
por: Hu, Yanmin, et al.
Publicado: (2016)

Effects on the QT Interval of a Gatifloxacin-Containing Regimen versus Standard Treatment of Pulmonary Tuberculosis
por: Olliaro, Piero L., et al.
Publicado: (2017)

Heterogeneous disease progression and treatment response in a C3HeB/FeJ mouse model of tuberculosis
por: Lanoix, Jean-Philippe, et al.
Publicado: (2015)

A Faropenem, Linezolid, and Moxifloxacin Regimen for Both Drug-Susceptible and Multidrug-Resistant Tuberculosis in Children: FLAME Path on the Milky Way
por: Deshpande, Devyani, et al.
Publicado: (2016)

Linking Murine and Human Plasmodium falciparum Challenge Models in a Translational Path for Antimalarial Drug Development
por: McCarthy, James S., et al.
Publicado: (2016)

Efficacy and Improved Resistance Potential of a Cofactor-Independent InhA Inhibitor of Mycobacterium tuberculosis in the C3HeB/FeJ Mouse Model
por: Robertson, Gregory T., et al.
Publicado: (2019)

Delamanid Added to an Optimized Background Regimen in Children with Multidrug-Resistant Tuberculosis: Results of a Phase I/II Clinical Trial
por: Garcia-Prats, Anthony J., et al.
Publicado: (2022)

Amikacin Optimal Exposure Targets in the Hollow-Fiber System Model of Tuberculosis
por: Srivastava, Shashikant, et al.
Publicado: (2016)

Intracellular Pharmacodynamic Modeling Is Predictive of the Clinical Activity of Fluoroquinolones against Tuberculosis
por: Donnellan, Samantha, et al.
Publicado: (2019)

Interaction of cimetidine with P450 in a mouse model of hepatocarcinogenesis initiation
por: Caballero, F, et al.
Publicado: (2002)

Daily Dosing for Bedaquiline in Patients with Tuberculosis
por: Salinger, David H., et al.
Publicado: (2019)

In silico toxicology models and databases as FDA Critical Path Initiative toolkits
por: Valerio, Luis G
Publicado: (2011)

Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model
por: Kendall, Emily A., et al.
Publicado: (2017)

Lung microenvironments harbor Mycobacterium tuberculosis phenotypes with distinct treatment responses
por: Walter, Nicholas D., et al.
Publicado: (2023)

A proposed conceptualization of therapeutic competence: the three level model
por: Koddebusch, Christine, et al.
Publicado: (2018)

QT Interval Prolongation with One or More QT-Prolonging Agents Used as Part of a Multidrug Regimen for Rifampicin-Resistant Tuberculosis Treatment: Findings from Two Pediatric Studies
por: Ali, Ali Mohamed, et al.
Publicado: (2023)

Spiropyrimidinetriones: a Class of DNA Gyrase Inhibitors with Activity against Mycobacterium tuberculosis and without Cross-Resistance to Fluoroquinolones
por: Basarab, Gregory S., et al.
Publicado: (2022)

Population pharmacodynamic modelling of midazolam induced sedation in terminally ill adult patients
por: Franken, Linda G., et al.
Publicado: (2017)

Combination of everolimus and tacrolimus: a potentially effective regimen for recalcitrant psoriasis
por: Wei, Kai-Che, et al.
Publicado: (2015)

β-Lactam Dosage Regimens in Septic Patients with Augmented Renal Clearance
por: Jacobs, Alexandra, et al.
Publicado: (2018)

Optoacoustically induced auditory brainstem responses in the mouse model enhanced through an absorbing film
por: Sorg, Katharina, et al.
Publicado: (2021)

Evaluation of the Efficacy of Doxycycline, Ciprofloxacin, Levofloxacin, and Co-trimoxazole Using In Vitro and In Vivo Models of Q Fever
por: Clay, K. A., et al.
Publicado: (2021)

T405, a New Penem, Exhibits In Vivo Efficacy against M. abscessus and Synergy with β-Lactams Imipenem and Cefditoren
por: Rimal, Binayak, et al.
Publicado: (2022)

PathBank: a comprehensive pathway database for model organisms
por: Wishart, David S, et al.
Publicado: (2020)

Treatment regimen determines whether an HIF-1 inhibitor enhances or inhibits the effect of radiation therapy
por: Harada, H, et al.
Publicado: (2009)

How are drug regimen changes during hospitalisation handled after discharge: a cohort study
por: Viktil, Kirsten K, et al.
Publicado: (2012)

Short‐Term Efficacy Reliably Predicts Long‐Term Clinical Benefit in Rheumatoid Arthritis Clinical Trials as Demonstrated by Model‐Based Meta‐Analysis
por: Wang, Yehong, et al.
Publicado: (2015)

Discovery of Novel Oral Protein Synthesis Inhibitors of Mycobacterium tuberculosis That Target Leucyl-tRNA Synthetase
por: Palencia, Andrés, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_817uf6k0his4tr4p6eb0t5704s